The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

But with Brukinsa and degraders looming, will fixed dosing make the difference?

Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.

The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.

The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.

Party season approaches; but first, conferences.